Vaso (OTCMKTS:VASO) and Envoy Medical (NASDAQ:COCH) Financial Analysis

Envoy Medical (NASDAQ:COCH) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Profitability

This table compares Envoy Medical and Vaso’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-9,857.26%	N/A	-256.65%
Vaso	2.91%	9.49%	3.16%

Volatility & Risk

Envoy Medical has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Vaso has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Insider and Institutional Ownership

8.6% of Envoy Medical shares are held by institutional investors. 5.7% of Envoy Medical shares are held by company insiders. Comparatively, 43.9% of Vaso shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Envoy Medical and Vaso, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1	0	1	0	2.00
Vaso	0	0	0	0	0.00

Envoy Medical currently has a consensus price target of $9.50, suggesting a potential upside of 1,355.72%. Given Envoy Medical’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Envoy Medical is more favorable than Vaso.

Valuation and Earnings

This table compares Envoy Medical and Vaso”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240,000.00	78.28	-$20.80 million	($1.22)	-0.53
Vaso	$86.77 million	0.35	$950,000.00	$0.01	17.49

Vaso has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Vaso, indicating that it is currently the more affordable of the two stocks.

Summary

Vaso beats Envoy Medical on 8 of the 14 factors compared between the two stocks.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

About Vaso

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.